We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$183M
Cap. Flow
-$318M
Cap. Flow %
-35.32%
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
34

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$25.1M
2
PEN icon
Penumbra
PEN
+$17.6M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$16.9M
4
GSK icon
GSK
GSK
+$12M
5
NUVL
Nuvalent
NUVL
+$10.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26M
2
ACLX
Arcellx
ACLX
+$21.9M
3
PODD icon
Insulet
PODD
+$20.4M
4
EOLS icon
Evolus
EOLS
+$19M
5
CRL icon
Charles River Laboratories
CRL
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$35.9B
$58.1M 6.45%
5,564,440
-487,724
-8% -$4.55M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$54.9M 6.09%
249,449
-37,716
-13% -$8.69M
GSK icon
3
GSK
GSK
$103B
$47.4M 5.26%
1,278,540
+335,540
+36% +$12M
RYZB
4
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$46.4M 5.15%
746,622
+295,459
+65% +$7.34M
FOCL
5
EDAP TMS S.A.
FOCL
$226M
$38.2M 4.23%
7,226,341
+969,557
+15% +$5.64M
ORGO icon
6
Organogenesis Holdings
ORGO
$308M
$36.7M 4.07%
8,963,000
-3,333,163
-27% -$9.33M
HUM icon
7
Humana
HUM
$46.7B
$33.7M 3.74%
73,706
+4,904
+7% +$2.42M
CELC icon
8
Celcuity
CELC
$4.03B
$31.8M 3.52%
2,179,481
+122,997
+6% +$1.49M
IRMD icon
9
iRadimed
IRMD
$1.21B
$30.5M 3.39%
643,206
+15,000
+2% +$631K
EPIX
10
DELISTED
ESSA Pharma
EPIX
$28.6M 3.17%
4,327,622
+40,528
+0.9% +$200K
SRDX
11
DELISTED
Surmodics
SRDX
$28.1M 3.11%
771,700
-459,162
-37% -$15M
HCA icon
12
HCA Healthcare
HCA
$84.8B
$27.5M 3.05%
+101,500
New +$25.1M
PCVX icon
13
Vaxcyte
PCVX
$7.89B
$26.1M 2.89%
415,450
-84,200
-17% -$4.37M
NPCE icon
14
Neuropace
NPCE
$505M
$25.1M 2.78%
2,433,168
-33,037
-1% -$263K
NUVL
15
DELISTED
Nuvalent
NUVL
$23.8M 2.64%
322,888
+168,472
+109% +$10.4M
MREO
16
Mereo BioPharma
MREO
$45.9M
$22.6M 2.51%
9,777,419
+100,000
+1% +$191K
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.41B
$20.1M 2.23%
+564,700
New +$16.9M
PEN icon
18
Penumbra
PEN
$12.5B
$20M 2.22%
+79,400
New +$17.6M
AXGN icon
19
Axogen
AXGN
$2.1B
$17.7M 1.97%
2,595,815
-1,190,014
-31% -$6.62M
ATRC icon
20
AtriCure
ATRC
$1.77B
$14M 1.55%
392,195
+86,195
+28% +$3.21M
RIGL icon
21
Rigel Pharmaceuticals
RIGL
$680M
$13.7M 1.52%
944,258
-536,044
-36% -$5.48M
IMVT icon
22
Immunovant
IMVT
$8.09B
$13.4M 1.48%
317,050
-82,549
-21% -$3.04M
TMCI icon
23
Treace Medical Concepts
TMCI
$259M
$12.9M 1.43%
1,014,005
-893,818
-47% -$9.03M
SNN icon
24
Smith & Nephew
SNN
$12.9B
$12.8M 1.42%
470,198
-183,702
-28% -$4.55M
VSTM icon
25
Verastem
VSTM
$532M
$11.6M 1.29%
1,425,634
+78,265
+6% +$562K
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Soleus Capital Management held 107 positions worth $901M, down 17% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management withdrew a net $318M in Q4 2023, closing 34 positions and reducing 34 holdings. Its most notable exit was Insulet, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $27.5M.

  • Soleus Capital Management's largest Q4 2023 buy was HCA Healthcare: 101,500 shares worth $27.5M.
  • Soleus Capital Management added most to GSK in Q4 2023, an estimated $12M increase.
  • Soleus Capital Management's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $26M.
  • Soleus Capital Management fully exited Insulet in Q4 2023, selling an estimated $20.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $901M portfolio in Q4 2023.
  • Soleus Capital Management opened 16 new positions and closed 34 in Q4 2023.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $901M.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.